Metabolic Consequences of Gestational Cannabinoid Exposure
Up to 20% of pregnant women ages 18-24 consume cannabis during pregnancy. Moreover, clinical studies indicate that cannabis consumption during pregnancy leads to fetal growth restriction (FGR), which is associated with an increased risk of obesity, type II diabetes (T2D), and cardiovascular disease...
Gespeichert in:
| Veröffentlicht in: | International journal of molecular sciences 2021-09, Vol.22 (17), p.9528 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 17 |
| container_start_page | 9528 |
| container_title | International journal of molecular sciences |
| container_volume | 22 |
| creator | Lee, Kendrick Hardy, Daniel B |
| description | Up to 20% of pregnant women ages 18-24 consume cannabis during pregnancy. Moreover, clinical studies indicate that cannabis consumption during pregnancy leads to fetal growth restriction (FGR), which is associated with an increased risk of obesity, type II diabetes (T2D), and cardiovascular disease in the offspring. This is of great concern considering that the concentration of Δ
- tetrahydrocannabinol (Δ9-THC), a major psychoactive component of cannabis, has doubled over the last decade and can readily cross the placenta and enter fetal circulation, with the potential to negatively impact fetal development via the endocannabinoid (eCB) system. Cannabis exposure in utero could also lead to FGR via placental insufficiency. In this review, we aim to examine current pre-clinical and clinical findings on the direct effects of exposure to cannabis and its constituents on fetal development as well as indirect effects, namely placental insufficiency, on postnatal metabolic diseases. |
| doi_str_mv | 10.3390/ijms22179528 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8430813</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2571237499</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-b0f6e6825b32ae356bfc0cdc70a4a73a40a58aaa351cd2118c6cd3a04aa6d7b73</originalsourceid><addsrcrecordid>eNpVkM1Lw0AQxRdRbK3ePEvAq9H9zCYehBJqFSpe9LxMNhvdku7W3UT0vzfSWuppHsyPN_MeQucEXzNW4Bu7XEVKiSwEzQ_QmHBKU4wzebinR-gkxiXGlFFRHKMR4wJTzrIxun0yHVS-tTopvYvmozdOm5j4Jpmb2EFnvYM2KcE5qKzztk5mX2sf-2BO0VEDbTRn2zlBr_ezl_IhXTzPH8vpItWc0C6tcJOZLKeiYhQME1nVaKxrLTFwkAw4BpEDABNE15SQXGe6ZoA5QFbLSrIJutv4rvtqZWptXBegVetgVxC-lQer_m-cfVdv_lPlnOGcsMHgcmsQ_JAvdmrp-zDEiooKSSiTvCgG6mpD6eBjDKbZXSBY_Tat9pse8Iv9r3bwX7XsB2lxexM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2571237499</pqid></control><display><type>article</type><title>Metabolic Consequences of Gestational Cannabinoid Exposure</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Lee, Kendrick ; Hardy, Daniel B</creator><creatorcontrib>Lee, Kendrick ; Hardy, Daniel B</creatorcontrib><description>Up to 20% of pregnant women ages 18-24 consume cannabis during pregnancy. Moreover, clinical studies indicate that cannabis consumption during pregnancy leads to fetal growth restriction (FGR), which is associated with an increased risk of obesity, type II diabetes (T2D), and cardiovascular disease in the offspring. This is of great concern considering that the concentration of Δ
- tetrahydrocannabinol (Δ9-THC), a major psychoactive component of cannabis, has doubled over the last decade and can readily cross the placenta and enter fetal circulation, with the potential to negatively impact fetal development via the endocannabinoid (eCB) system. Cannabis exposure in utero could also lead to FGR via placental insufficiency. In this review, we aim to examine current pre-clinical and clinical findings on the direct effects of exposure to cannabis and its constituents on fetal development as well as indirect effects, namely placental insufficiency, on postnatal metabolic diseases.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms22179528</identifier><identifier>PMID: 34502436</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Animals ; Apoptosis ; Cannabidiol ; Cannabinoid Receptor Agonists - adverse effects ; Cannabinoids ; Cannabis ; Cardiovascular disease ; Cardiovascular diseases ; Diabetes mellitus ; Dronabinol - adverse effects ; Exposure ; Female ; Fetal Growth Retardation - chemically induced ; Fetuses ; Genetic crosses ; Humans ; Intrauterine exposure ; Kinases ; Ligands ; Lipid Metabolism - drug effects ; Liver - drug effects ; Marijuana ; Metabolic Diseases - chemically induced ; Metabolic disorders ; Metabolism ; Placenta ; Placenta - drug effects ; Pregnancy ; Prenatal Exposure Delayed Effects ; Proteins ; Review ; Tetrahydrocannabinol</subject><ispartof>International journal of molecular sciences, 2021-09, Vol.22 (17), p.9528</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-b0f6e6825b32ae356bfc0cdc70a4a73a40a58aaa351cd2118c6cd3a04aa6d7b73</citedby><cites>FETCH-LOGICAL-c412t-b0f6e6825b32ae356bfc0cdc70a4a73a40a58aaa351cd2118c6cd3a04aa6d7b73</cites><orcidid>0000-0001-5445-273X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430813/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430813/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34502436$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Kendrick</creatorcontrib><creatorcontrib>Hardy, Daniel B</creatorcontrib><title>Metabolic Consequences of Gestational Cannabinoid Exposure</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Up to 20% of pregnant women ages 18-24 consume cannabis during pregnancy. Moreover, clinical studies indicate that cannabis consumption during pregnancy leads to fetal growth restriction (FGR), which is associated with an increased risk of obesity, type II diabetes (T2D), and cardiovascular disease in the offspring. This is of great concern considering that the concentration of Δ
- tetrahydrocannabinol (Δ9-THC), a major psychoactive component of cannabis, has doubled over the last decade and can readily cross the placenta and enter fetal circulation, with the potential to negatively impact fetal development via the endocannabinoid (eCB) system. Cannabis exposure in utero could also lead to FGR via placental insufficiency. In this review, we aim to examine current pre-clinical and clinical findings on the direct effects of exposure to cannabis and its constituents on fetal development as well as indirect effects, namely placental insufficiency, on postnatal metabolic diseases.</description><subject>Animals</subject><subject>Apoptosis</subject><subject>Cannabidiol</subject><subject>Cannabinoid Receptor Agonists - adverse effects</subject><subject>Cannabinoids</subject><subject>Cannabis</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Diabetes mellitus</subject><subject>Dronabinol - adverse effects</subject><subject>Exposure</subject><subject>Female</subject><subject>Fetal Growth Retardation - chemically induced</subject><subject>Fetuses</subject><subject>Genetic crosses</subject><subject>Humans</subject><subject>Intrauterine exposure</subject><subject>Kinases</subject><subject>Ligands</subject><subject>Lipid Metabolism - drug effects</subject><subject>Liver - drug effects</subject><subject>Marijuana</subject><subject>Metabolic Diseases - chemically induced</subject><subject>Metabolic disorders</subject><subject>Metabolism</subject><subject>Placenta</subject><subject>Placenta - drug effects</subject><subject>Pregnancy</subject><subject>Prenatal Exposure Delayed Effects</subject><subject>Proteins</subject><subject>Review</subject><subject>Tetrahydrocannabinol</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpVkM1Lw0AQxRdRbK3ePEvAq9H9zCYehBJqFSpe9LxMNhvdku7W3UT0vzfSWuppHsyPN_MeQucEXzNW4Bu7XEVKiSwEzQ_QmHBKU4wzebinR-gkxiXGlFFRHKMR4wJTzrIxun0yHVS-tTopvYvmozdOm5j4Jpmb2EFnvYM2KcE5qKzztk5mX2sf-2BO0VEDbTRn2zlBr_ezl_IhXTzPH8vpItWc0C6tcJOZLKeiYhQME1nVaKxrLTFwkAw4BpEDABNE15SQXGe6ZoA5QFbLSrIJutv4rvtqZWptXBegVetgVxC-lQer_m-cfVdv_lPlnOGcsMHgcmsQ_JAvdmrp-zDEiooKSSiTvCgG6mpD6eBjDKbZXSBY_Tat9pse8Iv9r3bwX7XsB2lxexM</recordid><startdate>20210902</startdate><enddate>20210902</enddate><creator>Lee, Kendrick</creator><creator>Hardy, Daniel B</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5445-273X</orcidid></search><sort><creationdate>20210902</creationdate><title>Metabolic Consequences of Gestational Cannabinoid Exposure</title><author>Lee, Kendrick ; Hardy, Daniel B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-b0f6e6825b32ae356bfc0cdc70a4a73a40a58aaa351cd2118c6cd3a04aa6d7b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Apoptosis</topic><topic>Cannabidiol</topic><topic>Cannabinoid Receptor Agonists - adverse effects</topic><topic>Cannabinoids</topic><topic>Cannabis</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Diabetes mellitus</topic><topic>Dronabinol - adverse effects</topic><topic>Exposure</topic><topic>Female</topic><topic>Fetal Growth Retardation - chemically induced</topic><topic>Fetuses</topic><topic>Genetic crosses</topic><topic>Humans</topic><topic>Intrauterine exposure</topic><topic>Kinases</topic><topic>Ligands</topic><topic>Lipid Metabolism - drug effects</topic><topic>Liver - drug effects</topic><topic>Marijuana</topic><topic>Metabolic Diseases - chemically induced</topic><topic>Metabolic disorders</topic><topic>Metabolism</topic><topic>Placenta</topic><topic>Placenta - drug effects</topic><topic>Pregnancy</topic><topic>Prenatal Exposure Delayed Effects</topic><topic>Proteins</topic><topic>Review</topic><topic>Tetrahydrocannabinol</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Kendrick</creatorcontrib><creatorcontrib>Hardy, Daniel B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Kendrick</au><au>Hardy, Daniel B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metabolic Consequences of Gestational Cannabinoid Exposure</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2021-09-02</date><risdate>2021</risdate><volume>22</volume><issue>17</issue><spage>9528</spage><pages>9528-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Up to 20% of pregnant women ages 18-24 consume cannabis during pregnancy. Moreover, clinical studies indicate that cannabis consumption during pregnancy leads to fetal growth restriction (FGR), which is associated with an increased risk of obesity, type II diabetes (T2D), and cardiovascular disease in the offspring. This is of great concern considering that the concentration of Δ
- tetrahydrocannabinol (Δ9-THC), a major psychoactive component of cannabis, has doubled over the last decade and can readily cross the placenta and enter fetal circulation, with the potential to negatively impact fetal development via the endocannabinoid (eCB) system. Cannabis exposure in utero could also lead to FGR via placental insufficiency. In this review, we aim to examine current pre-clinical and clinical findings on the direct effects of exposure to cannabis and its constituents on fetal development as well as indirect effects, namely placental insufficiency, on postnatal metabolic diseases.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>34502436</pmid><doi>10.3390/ijms22179528</doi><orcidid>https://orcid.org/0000-0001-5445-273X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2021-09, Vol.22 (17), p.9528 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8430813 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Animals Apoptosis Cannabidiol Cannabinoid Receptor Agonists - adverse effects Cannabinoids Cannabis Cardiovascular disease Cardiovascular diseases Diabetes mellitus Dronabinol - adverse effects Exposure Female Fetal Growth Retardation - chemically induced Fetuses Genetic crosses Humans Intrauterine exposure Kinases Ligands Lipid Metabolism - drug effects Liver - drug effects Marijuana Metabolic Diseases - chemically induced Metabolic disorders Metabolism Placenta Placenta - drug effects Pregnancy Prenatal Exposure Delayed Effects Proteins Review Tetrahydrocannabinol |
| title | Metabolic Consequences of Gestational Cannabinoid Exposure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T02%3A48%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metabolic%20Consequences%20of%20Gestational%20Cannabinoid%20Exposure&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Lee,%20Kendrick&rft.date=2021-09-02&rft.volume=22&rft.issue=17&rft.spage=9528&rft.pages=9528-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms22179528&rft_dat=%3Cproquest_pubme%3E2571237499%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2571237499&rft_id=info:pmid/34502436&rfr_iscdi=true |